Skip to main content
Premium Trial:

Request an Annual Quote

Incyte Says It May Buy Back $30M of Stock

NEW YORK, Oct. 14 - Incyte Genomics today said it may spend up to $30 million to buy back its own stock, which it says is undervalued.

 

The company said its shares "represent an attractive investment opportunity," and it might buy some of them back in the open market or in private transactions.

 

Shares in Incyte were up 14 cents, or 4.4 percent, at $3.29 on the Nasdaq exchange.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.